^
    CANCER:

    Thymic Carcinoma





    Show legend
    Group by Gene:
    Include preclinical:

    0
    PD1 inhibitor
    PD1 inhibitor
    pembrolizumab
    1
    mTOR inhibitor
    everolimus
    2
    DNA synthesis inhibitor
    gemcitabine
    3
    Tubulin polymerization promoter
    carboplatin
    4
    Topoisomerase II inhibitor, DNA inhibitor
    etoposide oral
    5
    Bifunctional alkylating agent
    ifosfamide
    6
    Multi-tyrosine kinase inhibitor
    anlotinib
    7
    PD-L1 inhibitor, CTLA4 inhibitor
    KN046
    8
    EGFR inhibitor
    icotinib
    LV5FU2
    GEM-CAP
    ADOC
    		9
    Chemotherapy
    EP
    CaT
    VIP
    CAP
    CAP
    10
    VEGFR inhibitor, PDGFR inhibitor, c-KIT inhibitor
    sunitinib
    11
    FGFR inhibitor, VEGFR inhibitor, RET inhibitor, c-KIT inhibitor, PDGFR α antagonist
    lenvatinib
    12
    Tubulin polymerization promoter, Bcl2 inhibitor
    paclitaxel
    13
    THF dehydrogenase inhibitor, Thymidylate synthase inhibitor
    pemetrexed
    14
    DNA synthesis inhibitor, Thymidylate synthase inhibitor
    gemcitabine + capecitabine
    15
    HER2 inhibitor, HER4 inhibitor, EGFR inhibitor
    pyrotinib
    16
    pan-RAF inhibitor, Multi-tyrosine kinase inhibitor
    sorafenib
    17
    PDGFR antagonist, mutant c-KIT inhibitor, CSF-1R inhibitor
    avapritinib
    18
    Mesothelin-targeted antibody-drug conjugate, Microtubule inhibitor
    BAY 94-9343
    No biomarker
    KIT mutation
    KIT D820Y
    KIT exon 17 mutation
    HER-2 positive
    HER-2 mutation
    PD-L1 overexpression
    EGFR exon 20 insertion
    EGFR exon 19 deletion
    PD-L1 expression
    SP140 overexpression
    MSLN expression
    EIF4EBP1 expression
    IGF1R expression